Dergiler / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 4

Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

Reji THOMAS, Mesut CETİN, Glen B. BAKER, M. Serdar DURSUN

Sayfa
329–331
DOI
—
Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide — AJindex